Related Experiment Video

Updated: Jul 18, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Strategies for MMP inhibition in cancer: innovations for the post-trial era

Christopher Mark Overall1, Carlos López-Otín

  • 1Department of Oral Biological and Medical Sciences, C.I.H.R. Group in Matrix Dynamics, University of British Columbia, V6T 1Z3, Canada.

Nature Reviews. Cancer
|September 5, 2002
PubMed

Insights

Targeting matrix metalloproteinases (MMPs) for cancer therapy has been challenging. New insights into MMP regulation offer novel strategies for developing effective anticancer therapeutics by blocking these enzymes.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Matrix metalloproteinases (MMPs) have long been implicated in tumor progression and metastasis.
  • Previous attempts to develop MMP inhibitors as anticancer drugs yielded disappointing clinical results.
  • The complex regulation of MMP activity necessitates a deeper understanding for therapeutic development.

Purpose of the Study:

  • To explore diverse strategies for targeting MMPs in cancer.
  • To identify promising therapeutic avenues for cancer treatment based on MMP inhibition.

Main Methods:

  • Review of existing literature on MMP function and regulation in cancer.
  • Analysis of clinical trial outcomes for MMP inhibitors.
  • Exploration of novel approaches to modulate MMP activity.

Main Results:

  • MMP inhibitors have historically shown limited efficacy in clinical trials.
  • MMP activity is subject to intricate multi-level regulation.
  • Emerging strategies focus on targeting specific MMPs or their regulatory pathways.

Conclusions:

  • Rethinking MMP-targeted cancer therapy is crucial.
  • Understanding MMP regulation provides new opportunities for drug development.
  • Targeting MMPs offers potential for novel anticancer strategies.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...